Methods and compositions for maintaining and expanding hematopoietic stem cells - Patents.com

A chemically defined culture medium using specific small molecule substances addresses inefficiencies in HSC expansion by optimizing signaling pathways, achieving rapid and robust HSC maintenance and expansion.

JP2024541616APending Publication Date: 2024-11-08TRAILHEAD BIOSYSTEMS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024532440
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-30
Filing Date
2022-11-29
Publication Date
2024-11-08

Smart Images

  • Figure 2024541616000004
    Figure 2024541616000004
  • Figure 2024541616000005
    Figure 2024541616000005
  • Figure 2024541616000006
    Figure 2024541616000006
Patent Text Reader

Abstract

Methods are provided for maintaining and expanding human CD34+ hematopoietic stem cells (HSCs) using a chemically defined culture medium, which allows for expansion of HSCs in as few as six days. Culture media, isolated cell populations, and kits are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims priority to U.S. Provisional Application No. 63 / 284,360, filed November 30, 2021, the entire contents of which are incorporated herein by reference. [Background technology]

[0002] 2. Background of the Invention Hematopoietic stem cells (HSCs) are multipotent, self-renewing cells that give rise to the entire hematopoietic system, including cells of the myeloid and lymphoid lineages. HSCs are rare cells found naturally in bone marrow and umbilical cord blood, and even more rarely in peripheral blood. HSCs are usually defined by the expression or lack of expression of certain markers, such as expression of CD34 and lack of expression of lineage-specific markers and CD38 (Lin-CD34+CD38-). Allogeneic HSCs have been used in stem cell transplantation as a means of treating serious blood disorders, including cancers such as leukemia and lymphoma, and autoimmune diseases. However, the use of HSCs for transplantation requires the ability to isolate, expand, and maintain HSCs in culture, given their very limited natural presence.

[0003] Various culture systems for expanding CD34+ HSCs have been described, typically including culture media supplemented with stem cell factor (SCF) and thrombopoietin (TPO) along with other cytokines and small molecules. For example, Nishino et al. reported expanding HSCs by culturing them for 7 days in a medium containing SCF, TPO, and garcinol, a potent inhibitor of histone acetyltransferase (Nishino et al. (2011) PLoS One 6:e24298). Himburg et al. reported expanding HSCs by culturing them in a medium containing SCF, TPO, Flt-3 ligand, and pleiotrophin, the latter of which activates PI3K signaling (Himburg et al. (2010) Nat. Med. 16:475-482). Cord blood-derived CD34+ HSCs have been expanded ex vivo by culturing in basal medium containing SCF, TPO, Flt-3 ligand, and low density lipoprotein, to which an inhibitor of the JNK pathway has been added (Xiao et al. (2019) Cell. Discovery 5:2). Alternatively, cord blood-derived CD34+ HSCs were expanded ex vivo by culturing in medium containing SCF, TPO, Flt-3, and IL-3 for 16 hours, followed by the addition of the deacetylase inhibitor valproic acid (VPA) for an additional 7 days (Papa et al. (2019) J. Vis. Exp. DOI:10.3791 / 59532).

[0004] Aryl hydrocarbon receptor antagonists, such as the purine derivative SR1, have been reported to promote the expansion and proliferation of HSCs (Boitano et al. (2010) Science 329:1345-1348 (Non-Patent Document 5)).

[0005] It has been reported that antagonizing peroxisome proliferator-activated receptor (PPAR) gamma promotes the expansion and proliferation of HSCs (Guo et al. (2018) Nat. Med. 24:360-367 (Non-Patent Document 6)).

[0006] Recently, it has been reported that the addition of an inhibitor of the NFκB signaling pathway for 10 days enhances the expansion and proliferation of HSCs in culture (Sun et al. (2021) Exp. Cell. Res. 399:112468 (Non-Patent Document 7)).

[0007] Furthermore, through screening of a panel of 186 chemicals, a combination of CHIR-99021 (GSK3 inhibitor), forskolin (cAMP activator), and OAC1 (Oct4 activator) was identified as a chemical cocktail that supports the maintenance of HSCs in culture (Jiang et al. (2018) Cell. Discovery 4:59).

[0008] Thus, despite some progress, there remains a need for efficient and robust methods and compositions for expanding and maintaining HSCs in culture. [Prior art documents] [Non-patent literature]

[0009] [Non-Patent Document 1] Nishino et al. (2011) PLoS One 6:e24298 [Non-Patent Document 2] Himburg et al. (2010) Nat. Med. 16:475-482 [Non-Patent Document 3] Xiao et al. (2019) Cell. Discovery 5:2 [Non-Patent Document 4] Papa et al. (2019) J. Vis. Exp. DOI:10.3791 / 59532 [Non-Patent Document 5] Boitano et al. (2010) Science 329:1345-1348 [Non-Patent Document 6] Guo et al. (2018) Nat. Med. 24:360-367 [Non-Patent Document 7] Sun et al. (2021) Exp. Cell. Res. 399:112468 [Non-Patent Document 8] Jiang et al. (2018) Cell. Discovery 4:59 Summary of the Invention

[0010] The present disclosure provides a method for maintaining and expanding human hematopoietic stem cells (HSCs), e.g., from umbilical cord blood or bone marrow cells, using a chemically defined culture medium, which allows for the expansion of CD34+ HSCs in as little as 6 days of culture. The culture medium is serum-free and contains small molecule substances that agonize or antagonize specific signaling pathways in stem cells, resulting in the promotion of expansion and self-renewal along the CD34+ HSC lineage, leading to the expression of HSC-associated biomarkers. The method of the present disclosure has the advantage of significantly shortening the time required to expand CD34+ HSCs. Furthermore, the use of small molecule substances in the culture medium allows for precise control of culture components.

[0011] Thus, in one aspect, the present disclosure relates to a method for maintaining or expanding human CD34+ hematopoietic stem cells (HSCs), comprising culturing the human CD34+ HSCs in a culture medium comprising a c-kit ligand, a TPOR agonist, a TGFβ pathway agonist, an antioxidant, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, a Notch agonist, and a histone deacetylase (HDAC) inhibitor.

[0012] In some embodiments, the c-kit ligand is stem cell factor (SCF).

[0013] In some embodiments, the TPOR agonist is thrombopoietin (TPO). In other embodiments, the TPOR agonist is eltrombopag, TA-316, TPO agonist 1, avatrombopag, or lusutrombopag.

[0014] In one embodiment, the TGFβ pathway agonist is activin A. In another embodiment, the TGFβ pathway agonist is alantolactone.

[0015] In some embodiments, the antioxidant is a form of vitamin C (ascorbic acid), such as L-ascorbic acid phosphate sesquimagnesium salt hydrate (Vit. C), a stable form of vitamin C. In other embodiments, the antioxidant is ascorbic acid, glutathione, ebselen, N-acetyl-L-cysteine, or α-tocopherol.

[0016] In some embodiments, the bioactive phospholipid is lysophosphatidic acid (LPA). In other embodiments, the bioactive phospholipid is sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P), or lysophosphatidylcholine (LPC).

[0017] In some embodiments, the AhR agonist is 6-formylindolo[3,2-b]carbazole (FICZ). In other embodiments, the AhR agonist is norisoboldine, pifithrin-α hydrobromide, MeBIO, ITE, or 10-Cl-BBQ.

[0018] In some embodiments, the Notch agonist is Yhhu 3792. In other embodiments, the Notch agonist is Jagged 1-2 or DLL1-4.

[0019] In some embodiments, the HDAC inhibitor is valproic acid (VPA). In other embodiments, the HDAC inhibitor is vorinostat, entinostat, panobinostat, trichostatin A, mocetinostat, 4-phenylbutyric acid, ACY-775, GSK3117391, belinostat, romidepsin, MC1568, tubastatin A, gibinostat, dacinostat, CUDC-101, xinostat, pracinostat, PCI-34051, droxinostat, abexinostat, RGFP966, AR-42, ricorinostat, tacedinaline, fimepinostat, sodium butyrate, curcumin, M344, tubacin, RG2833, resminostat, divalproex sodium, scriptaid, sodium phenylbutyrate, tubastatin. and the like. The compound is selected from the group consisting of sinostat A, sinapic acid, TMP269, CAY10683, TMP195, UF010, tasquinimod, SKLb-23bb, isoguanosine, NKL22, sulforaphane, BRD73594, citalinostat, suberohydroxamic, BRD3308, splitomycin, HPOB, LMK235, biphenyl-4-sulfonyl chloride, nextulastat A, BML-210, TC-H106, SR-4370, TH34, tushidinostat, SIS17, parthenolide, wt161, CAY10603, ACY738, raddeanin A, tinostamustin, domatinostat, BG45, and ITSA-1.

[0020] In one embodiment, a method for maintaining or expanding human CD34+ hematopoietic stem cells (HSCs) comprises culturing human CD34+ HSCs in a culture medium comprising stem cell factor (SCF), thrombopoietin (TPO), activin A, vitamin C, lysophosphatidic acid (LPA), 6-formylindolo[3,2-b]carbazole (FICZ), Yhhu 3792, and valproic acid (VPA). In one embodiment, SCF is present at a concentration of 10 ng / ml, TPO is present at a concentration of 100 ng / ml, activin A is present at a concentration of 20 ng / ml, vitamin C is present at a concentration of 100 μM, LPA is present at a concentration of 200 nM, FICZ is present at a concentration of 500 nM, Yhhu 3792 is present at a concentration of 750 nM, and VPA is present at a concentration of 150 μM.

[0021] In the methods and compositions of the disclosure, the CD34+ HSCs can be derived, for example, from umbilical cord blood or bone marrow.

[0022] In certain embodiments, the CD34+ HSCs are cultured in the medium described herein for at least 6 days (eg, 7 days, or a week or more).

[0023] In some embodiments, the CD34+ HSCs have a phenotype of Lin-CD34+CD38-CD45RA-CD90+.

[0024] In another aspect, the present disclosure relates to a culture medium for expanding or maintaining human CD34+ hematopoietic stem cells (HSCs), comprising a c-kit ligand, a TPOR agonist, a TGFβ pathway agonist, an antioxidant, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, a Notch agonist, and a histone deacetylase (HDAC) inhibitor.

[0025] In some embodiments, the c-kit ligand is stem cell factor (SCF).

[0026] In some embodiments, the TPOR agonist is thrombopoietin (TPO). In other embodiments, the TPOR agonist is eltrombopag, TA-316, TPO agonist 1, avatrombopag, or lusutrombopag.

[0027] In one embodiment, the TGFβ pathway agonist is activin A. In another embodiment, the TGFβ pathway agonist is alantolactone.

[0028] In some embodiments, the antioxidant is vitamin C. In other embodiments, the antioxidant is ascorbic acid, glutathione, ebselen, N-acetyl-L-cysteine, or alpha-tocopherol.

[0029] In some embodiments, the bioactive phospholipid is lysophosphatidic acid (LPA). In other embodiments, the bioactive phospholipid is sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P), or lysophosphatidylcholine (LPC).

[0030] In some embodiments, the AhR agonist is 6-formylindolo[3,2-b]carbazole (FICZ). In other embodiments, the AhR agonist is norisoboldine, pifithrin-α hydrobromide, MeBIO, ITE, or 10-Cl-BBQ.

[0031] In some embodiments, the Notch agonist is Yhhu 3792. In other embodiments, the Notch agonist is Jagged 1-2 or DLL1-4.

[0032] In some embodiments, the HDAC inhibitor is valproic acid (VPA). In other embodiments, the HDAC inhibitor is vorinostat, entinostat, panobinostat, trichostatin A, mocetinostat, 4-phenylbutyric acid, ACY-775, GSK3117391, belinostat, romidepsin, MC1568, tubastatin A, gibinostat, dacinostat, CUDC-101, xinostat, pracinostat, PCI-34051, droxinostat, abexinostat, RGFP966, AR-42, ricorinostat, tacedinaline, fimepinostat, sodium butyrate, curcumin, M344, tubacin, RG2833, resminostat, divalproex sodium, scriptaid, sodium phenylbutyrate. rhamnosine, tubastatin A, sinapic acid, TMP269, CAY10683, TMP195, UF010, tasquinimod, SKLb-23bb, isoguanosine, NKL22, sulforaphane, BRD73594, citalinostat, suberohydroxamic, BRD3308, splitomycin, HPOB, LMK235, biphenyl-4-sulfonyl chloride, nextulastat A, BML-210, TC-H106, SR-4370, TH34, tushidinostat, SIS17, parthenolide, wt161, CAY10603, ACY738, raddeanin A, tinostamustin, domatinostat, BG45, and ITSA-1.

[0033] In some embodiments, the culture medium comprises stem cell factor (SCF), thrombopoietin (TPO), activin A, vitamin C, lysophosphatidic acid (LPA), 6-formylindolo[3,2-b]carbazole (FICZ), Yhhu 3792, and valproic acid (VPA). In some embodiments, SCF is present at a concentration of 10 ng / ml, TPO is present at a concentration of 100 ng / ml, activin A is present at a concentration of 20 ng / ml, vitamin C is present at a concentration of 100 μM, LPA is present at a concentration of 200 nM, FICZ is present at a concentration of 500 nM, Yhhu 3792 is present at a concentration of 750 nM, and VPA is present at a concentration of 150 μM.

[0034] In yet another aspect, the present disclosure relates to an isolated cell culture of human CD34+ hematopoietic stem cells (HSCs), comprising human CD34+ HSCs cultured in a culture medium comprising a c-kit ligand, a TPOR agonist, a TGFβ pathway agonist, an antioxidant, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, a Notch agonist, and a histone deacetylase (HDAC) inhibitor. Suitable agents include those described above.

[0035] In yet another aspect, the present disclosure relates to a method for maintaining human CD34+ long-term hematopoietic stem cells (LT-HSCs), comprising culturing human CD34+ HSCs in a culture medium comprising a TGFβ pathway agonist, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, and a histone deacetylase (HDAC) inhibitor, wherein the culture medium lacks stem cell factor (SCF) and thrombopoietin (TPO).Non-limiting examples of suitable agents and their concentrations include those described above.In one embodiment, the TGFβ pathway agonist is activin A, the bioactive phospholipid is lysophosphatidic acid (LPA), the AhR agonist is 6-formylindolo[3,2-b]carbazole (FICZ), and the HDAC inhibitor is valproic acid (VPA). In certain embodiments, LT-HSCs are CD34+ cells that also express CRHBP, HOPX, and LMO2.

[0036] In another aspect, the present disclosure provides a culture medium for maintaining human CD34+ long-term hematopoietic stem cells (LT-HSCs), comprising a TGFβ pathway agonist, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, and a histone deacetylase (HDAC) inhibitor, the culture medium lacking stem cell factor (SCF) and thrombopoietin (TPO).In another aspect, the present disclosure provides an isolated cell culture of human CD34+ LH-HSCs, comprising human CD34+ long-term hematopoietic stem cells (LT-HSCs) cultured in a culture medium comprising a TGFβ pathway agonist, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, and a histone deacetylase (HDAC) inhibitor, the culture medium lacking stem cell factor (SCF) and thrombopoietin (TPO).

[0037] Other features and advantages of the invention will become apparent from the following detailed description, and from the claims. [Brief description of the drawings]

[0038] [Figure 1] Results from an HD-DoE model of an eight-factor experiment optimized for maximum expression of GATA2 are shown. The top row of the model shows the predicted expression levels of 53 preselected genes when optimized for GATA2. The bottom row of the model shows the effectors tested in the model and their contribution to maximum expression of GATA2. The value column shows the concentration of each effector required to mimic the model. [Diagram 2] Dynamic profiles of expression levels of GATA2, CRHBP and MEG3 genes against the concentrations of eight effectors tested. The positive effects of LPA, FCIZ, Vit. C and Activin A on GATA2 expression and their factorial contributions are indicated by the slope of the plot for each effector. [Diagram 3]Figure 1 shows the results from an HD-DoE model of an eight-factor experiment optimized for maximum expression of CRHBP. The top row of the model shows the predicted expression levels of 53 preselected genes when optimized for CRHBP. The bottom row of the model shows the effectors tested in the model and their contribution to maximum expression of CRHBP. The value column shows the concentration of each effector required to mimic the model. [Figure 4] Dynamic profiles of CRHBP, GATA2 and MEG3 gene expression levels versus concentrations of five effectors tested. The positive effect of VPA on the expression of all three genes and their factorial contributions are indicated by the slope of the plot for each effector. [Diagram 5] Figure 1 shows the results from an HD-DoE model of an eight-factor experiment optimized for maximum expression of CRHBP. The top row of the model shows the predicted expression levels of 53 preselected genes when optimized for CRHBP. The bottom row of the model shows the effectors tested in the model and their contribution to maximum expression of CRHBP. The value column shows the concentration of each effector required to mimic the model. [Figure 6A] Figures 6A-B show the dynamic profile of expression levels of GATA2, HOXA5, and MEG3 genes against the concentrations of four validated effectors (FICZ, LPA, Vit. C, Activin A) for the expansion and proliferation of HSCs. Figure 6A shows the expression levels of the genes of interest in the presence of all five finalized effectors. [Figure 6B] Figure 6A-B show the dynamic profile of expression levels of GATA2, HOXA5 and MEG3 genes against the concentration of four validated effectors (FICZ, LPA, Vit. C, Activin A) for the expansion and proliferation of HSCs. Figure 6B shows the expression levels of genes of interest when one of the finalized effectors is absent at a time and the other effectors are present. [Figure 7A]Figures 7A-B show the dynamic profile of expression levels of GATA2, HOXA5, and MEG3 genes versus the concentration of one validated effector (VPA) for HSC expansion. Figure 7A shows the expression levels of genes of interest in the presence of VPA. [Figure 7B] Figure 7A-B show the dynamic profile of expression levels of GATA2, HOXA5, and MEG3 genes against the concentration of one validated effector (VPA) for HSC expansion. Figure 7B shows the expression levels of genes of interest in the absence of VPA. [Figure 8A] Figures 8A-B show the dynamic profile of expression levels of GATA2, HOXA5, and MEG3 genes versus the concentration of one validated effector (Yhhu 3792) for the expansion and proliferation of HSCs. Figure 8A shows the expression levels of genes of interest in the presence of Yhhu 3792. [Figure 8B] Figure 8A-B shows the dynamic profile of expression levels of GATA2, HOXA5 and MEG3 genes against the concentration of one validated effector (Yhhu 3792) for the expansion and proliferation of HSCs. Figure 8B shows the expression levels of genes of interest in the absence of Yhhu 3792. [Figure 9] Figures 9A-B show the results of flow cytometry analysis of cord blood CD34 cells cultured for 7 days with the developed HSC formulations (Figure 9A) or the control formulations (SCF and TPO) (Figure 9B) shown in Table 1. Cells were stained with antibodies against Lin, CD34, CD38, CD45RA, CD90, and the live / dead marker FVS700 to exclude dead cells from the analysis. [Figure 10] Figure 1 shows the results from the HD-DoE model of a 12-factor experiment optimized for maximum expression of CRHBP. The top row of the model shows the predicted expression levels of 53 preselected genes when optimized for CRHBP. The bottom row of the model shows the effectors tested in the model and their contribution to maximum expression of CRHBP. The value column shows the concentration of each effector required to mimic the model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] Detailed Description of the Invention Described herein are methodologies and compositions that enable the maintenance and expansion of human CD34+ hematopoietic stem cells (HSCs) under chemically defined culture conditions using a small molecule-based approach. A High-Dimensional Design of Experiments (HD-DoE) approach was employed to simultaneously test multiple process inputs (e.g., small molecule agonists or antagonists) on output responses such as gene expression, as described in Example 1. These experiments allowed the identification of chemically defined culture media containing agonists and / or antagonists of specific signaling pathways sufficient to maintain and expand HSCs in a very short time. The optimized culture media was further validated by factor importance analysis examining the impact of omitting individual agonist or antagonist agents, as described in Example 2. Flow cytometry analysis further confirmed the phenotype of cells generated by the differentiation protocol, as described in Example 3. Sub-protocols for maintaining long-term HSCs (LT-HSCs) were also determined, as described in Example 4.

[0040] Various aspects of the invention are described in further detail in the following subsections.

[0041] I. cell The starting cells used in the culture of the present disclosure are human CD34+ hematopoietic stem cells. As used herein, the term "hematopoietic stem cells" (abbreviated as HSC) refers to stem cells that have the ability to differentiate into a variety of different hematopoietic cell types. CD34 is a transmembrane phosphoglycoprotein that has been established in the art as a surface marker for HSC. Human HSCs can be easily obtained from available sources, such as human umbilical cord blood and adult bone marrow. HSCs include both long-term HSCs (LT-HSCs) and short-term HSCs (ST-HSCs).

[0042] Long-term HSCs (LT-HSCs) are HSCs present in bone marrow or umbilical cord blood that, through a process of asymmetric cell division, can either self-renew to maintain the stem cell pool or differentiate into short-term HSCs (ST-HSCs) or lineage-restricted progenitors that undergo extensive proliferation and differentiation to give rise to terminally differentiated cells of blood lineages. LT-HSCs are considered to be enriched in a fraction of Lin-CD34+CD38-CD45RA-CD90+ cells. LT-HSCs are quiescent and divide slowly in culture, taking up to 80 hours before their first cell division (Cheung and Rando (2013) Nat. Rev. Mol. Cell Biol. 14:329-340). In contrast, short-term HSCs (ST-HSCs) by definition have limited self-renewal capacity and are generally expected to undergo lymphohematopoiesis for 4–12 weeks before senescence.

[0043] In some embodiments, the HSCs express CD34 (CD34+). In some embodiments, the HSCs lack expression of lineage markers (Lin-). In some embodiments, the HSCs lack expression of CD38 (CD38-). In some embodiments, the HSCs lack expression of CD45RA (CD45RA-). In some embodiments, the HSCs express CD90 (CD90+). In some embodiments, the HSCs are Lin-CD34+CD38-CD45RA-CD90+ cells.

[0044] In some embodiments, the HSCs express one or more genes associated with the HSC phenotype (also referred to herein as HSC-associated genetic markers), non-limiting examples of which include CHRBP, Mecom, Meg3, HOPX, LMO2, CD34, TAL1, and GATA2.

[0045] In some embodiments, the LT-HSCs are CD34+. In some embodiments, the LT-HSCs are CD34+ and also express CRHBP, HOPX, and LMO2.

[0046] II. Culture medium components The disclosed method for maintaining and / or expanding CD34+ HSCs includes culturing human CD34+ HSCs in a culture medium containing specific agonists and / or antagonists of cell receptors and / or signaling pathways.

[0047] As described in Example 1, culture medium containing c-kit ligand, TPOR agonist, TGFβ pathway agonist, antioxidants, bioactive phospholipids, aryl hydrocarbon receptor (AhR) agonist, Notch agonist, and histone deacetylase (HDAC) inhibitors was sufficient to maintain and expand CD34+ HSCs in as few as 6 days.

[0048] Furthermore, a culture medium containing a TGFβ pathway agonist, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, and a histone deacetylase (HDAC) inhibitor was developed to maintain LT-HSCs, as described in Example 4. This culture medium lacks c-kit ligand and TPOR agonist, thus endowing LT-HSCs with low proliferation capacity.

[0049] As used herein, an "agonist" of a cell receptor or signal transduction pathway refers to a substance that stimulates (upregulates) a cell receptor or signal transduction pathway. Stimulation of a cell signal transduction pathway can be initiated extracellularly, for example, by the use of an agonist (e.g., the agonist can be a receptor ligand) that activates a cell surface receptor involved in the signal transduction pathway. Additionally or alternatively, stimulation of cell signal transduction can be initiated intracellularly, for example, by the use of a small molecule agonist that interacts intracellularly with a component of the signal transduction pathway.

[0050] As used herein, the term "antagonist" of a cell signaling pathway refers to a substance that inhibits (downregulates) a cell signaling pathway. Inhibition of a cell signaling pathway can be initiated extracellularly, for example, by using an antagonist that blocks cell surface receptors involved in the signaling pathway. Additionally or alternatively, inhibition of cell signaling can be initiated intracellularly, for example, by using a small molecule antagonist that interacts intracellularly with a component of the signaling pathway.

[0051] C-kit ligand, TPOR agonist, TGFβ pathway agonist, antioxidant, bioactive phospholipid, aryl hydrocarbon receptor (AhR) agonist, Notch agonist and histone deacetylase (HDAC) inhibitor are known in the art and are commercially available.They are used in culture medium at effective concentrations to achieve desired results, such as maintaining and / or expanding the HSCs that express markers of interest.Non-limiting examples of suitable agonists and antagonists, as well as effective concentration ranges, are further described below.

[0052] C-kit ligands include drugs, molecules, compounds or substances that bind to the c-kit receptor (CD117). In one embodiment, the c-kit ligand is stem cell factor (SCF). In one embodiment, the SCF is present in the medium at a concentration ranging from 5 to 25 ng / ml. In one embodiment, the SCF is present in the medium at a concentration of 10 ng / ml.

[0053] TPOR agonists include drugs, molecules, compounds or substances that agonize the thrombopoietin receptor (TPOR). In one embodiment, the TPOR agonist is thrombopoietin (TPO). In other embodiments, the TPOR agonist is eltrombopag, TA-316, TPO agonist 1, avatrombopag, or lusutrombopag. In one embodiment, the TPOR agonist is TPO, which is present in the medium at a concentration range of 50-150 ng / ml. In one embodiment, the TPOR agonist is TPO, which is present in the medium at a concentration of 100 ng / ml.

[0054] Agonists of the TGFβ pathway include drugs, molecules, compounds, or substances that can stimulate (activate) the TGFβ signaling pathway. In one embodiment, the TGFβ pathway agonist is activin A. In another embodiment, the TGFβ pathway agonist is alantolactone. In one embodiment, the TGFβ pathway agonist is activin A, which is present in the medium at a concentration range of 10-30 ng / ml. In one embodiment, the TGFβ pathway agonist is activin A, which is present in the medium at a concentration of 20 ng / ml.

[0055] Antioxidants include agents, molecules, compounds, or substances that prevent or slow damage to cells by free radicals. In some embodiments, the antioxidant is vitamin C. In one embodiment, the vitamin C is L-ascorbic acid phosphate sesquimagnesium salt hydrate (Vit. C), a stable form of vitamin C. In other embodiments, the antioxidant is ascorbic acid, glutathione, ebselen, N-acetyl-L-cysteine, or α-tocopherol. In some embodiments, the antioxidant is vitamin C, which is present in the medium at a concentration range of 50-150 μM. In some embodiments, the antioxidant is vitamin C, which is present in the medium at a concentration of 100 μM.

[0056] In some embodiments, the bioactive phospholipid is lysophosphatidic acid (LPA). In other embodiments, the bioactive phospholipid is sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P), or lysophosphatidylcholine (LPC). In some embodiments, the bioactive phospholipid is LPA, which is present in the medium at a concentration ranging from 100 to 300 μM. In some embodiments, the bioactive phospholipid is LPA, which is present in the medium at a concentration of 200 μM.

[0057] Agonists of AhR include drugs, molecules, compounds, or substances that can stimulate (activate) the AhR signaling pathway. In one embodiment, the AhR agonist is 6-formylindolo[3,2-b]carbazole (FICZ). In other embodiments, the AhR agonist is norisoboldine, pifithrin-α hydrobromide, MeBIO, ITE, or 10-Cl-BBQ. In one embodiment, the AhR agonist is FICZ, which is present in the medium at a concentration range of 250-750 nM. In one embodiment, the AhR agonist is FICZ, which is present in the medium at a concentration of 500 nM.

[0058] Agonists of Notch include drugs, molecules, compounds, or substances that can stimulate (activate) the Notch signaling pathway. In one embodiment, the Notch agonist is Yhhu 3792. In other embodiments, the Notch agonist is Jagged 1-2 or DLL1-4. In one embodiment, the Notch agonist is Yhhu 3792, which is present in the medium at a concentration range of 500-1000 nM. In one embodiment, the Notch agonist is Yhhu 3792, which is present in the medium at a concentration of 750 nM.

[0059] In some embodiments, the HDAC inhibitor is valproic acid (VPA). In other embodiments, the HDAC inhibitor is vorinostat, entinostat, panobinostat, trichostatin A, mocetinostat, 4-phenylbutyric acid, ACY-775, GSK3117391, belinostat, romidepsin, MC1568, tubastatin A, gibinostat, dacinostat, CUDC-101, xinostat, pracinostat, PCI-34051, droxinostat, abexinostat, RGFP966, AR-42, ricorinostat, tacedinaline, fimepinostat, sodium butyrate, curcumin, M344, tubacin, RG2833, resminostat, divalproex sodium, scriptaid, sodium phenylbutyrate. rhamnosine, tubastatin A, sinapic acid, TMP269, CAY10683, TMP195, UF010, tasquinimod, SKLb-23bb, isoguanosine, NKL22, sulforaphane, BRD73594, citalinostat, suberohydroxamic, BRD3308, splitomycin, HPOB, LMK235, biphenyl-4-sulfonyl chloride, nextulastat A, BML-210, TC-H106, SR-4370, TH34, tushidinostat, SIS17, parthenolide, wt161, CAY10603, ACY738, raddeanin A, tinostamustin, domatinostat, BG45, and ITSA-1. In one embodiment, the HDAC inhibitor is VPA, which is present in the medium at a concentration ranging from 100 to 200 μM. In one embodiment, the HDAC inhibitor is VPA, which is present in the medium at a concentration of 150 μM.

[0060] In some embodiments, a method of expanding or maintaining human CD34+ hematopoietic stem cells (HSCs) comprises culturing human CD34+ HSCs in a culture medium comprising stem cell factor (SCF), thrombopoietin (TPO), activin A, vitamin C, lysophosphatidic acid (LPA), 6-formylindolo[3,2-b]carbazole (FICZ), Yhhu3792, and valproic acid (VPA). In some embodiments, these agents are present in the medium at the concentration ranges described above. In one embodiment, SCF is present at a concentration of 10 ng / ml, TPO is present at a concentration of 100 ng / ml, activin A is present at a concentration of 20 ng / ml, vitamin C is present at a concentration of 100 μM, LPA is present at a concentration of 200 nM, FICZ is present at a concentration of 500 nM, Yhhu 3792 is present at a concentration of 750 nM, and VPA is present at a concentration of 150 μM.

[0061] III. Culture conditions In combination with the chemically defined and optimized culture medium described in subsection II above, the disclosed method of maintaining or expanding CD34+ HSC utilizes standard culture conditions established in the art for cell culture. For example, cells can be cultured at 37°C under conditions of 5% O2 and 5% CO2. A basal medium is used as the starting medium, to which supplementary substances can be added. For example, in one embodiment, commercially available StemSpan™ SFEM II medium is used as the basal medium. Cells can be cultured in standard culture vessels or plates, such as culture dishes, culture flasks, 96-well plates, etc.

[0062] Starting CD34+ HSCs can be obtained by methodologies established in the art. Sources of human CD34+ HSCs include umbilical cord blood and bone marrow. CD34+ HSCs can be obtained, for example, by standard magnetic enrichment.

[0063] To expand CD34+ HSCs, the cells are cultured in an optimized culture medium for a time sufficient to expand the CD34+ HSC population (i.e., to increase the number of CD34+ HSCs in the culture). As described in the Examples, it has been found that as little as 6 days of culture of CD34+ HSCs in an optimized culture medium is sufficient for the expansion of CD34+ HSCs and expression of desired cell markers.

[0064] In various embodiments, CD34+ HSCs are cultured in an optimized culture medium for a sufficient time to increase the expression of at least one, preferably a plurality of HSC-associated gene markers. Non-limiting examples of suitable HSC-associated gene markers include CHRBP, Mecom, Meg3, HOPX, LMO2, CD34, TAL1, and GATA2. In some embodiments, the cells are cultured for a sufficient time to increase the expression level of at least two, at least three, at least four, at least five, at least six, at least seven, or at least eight HSC-associated gene markers. In some embodiments, the cells are cultured for a sufficient time to increase the expression level of at least one HSC-associated gene marker (e.g., CHRBP) by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to the starting cell population. The expression level of gene markers in cultured HSCs can be measured by techniques available in the art (e.g., RNAseq analysis).

[0065] In certain embodiments, the cells are cultured for at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 10 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, or more.

[0066] The culture medium is typically replaced with fresh medium periodically, for example, in one embodiment, the medium is replaced every 72 hours.

[0067] IV. Purpose The disclosed method and composition for maintaining and expanding HSCs allows these cell populations to be efficiently and robustly utilized for various applications.For example, the disclosed method and composition can be used to study the development and differentiation of HSCs, including their biology to help understand hematopoiesis-related diseases and disorders.For example, the HSCs (e.g., LT-HSCs) produced using the disclosed method can be further purified according to established methods in the art using substances that bind to surface markers expressed on cells.

[0068] Additionally, it is contemplated that HSCs maintained and / or expanded according to the methods of the present disclosure can be used to treat a variety of hematopoietic diseases and disorders through delivery of the cells (e.g., HSC transplantation) to a subject having a hematopoietic disease or disorder. Examples of hematopoietic diseases and disorders include, but are not limited to, cancers such as leukemia and lymphoma, blood diseases, and autoimmune diseases.

[0069] V. composition In other aspects, the disclosure provides compositions relating to methods of maintaining and expanding HSCs, including culture media and isolated cell cultures.

[0070] In one aspect, the present disclosure provides a culture medium for maintaining or expanding human CD34+ hematopoietic stem cells (HSCs), comprising a c-kit ligand, a TPOR agonist, a TGFβ pathway agonist, an antioxidant, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, a Notch agonist, and a histone deacetylase (HDAC) inhibitor. In another aspect, the present disclosure provides a culture medium for maintaining human CD34+ long-term hematopoietic stem cells (LT-HSCs), comprising a TGFβ pathway agonist, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, and a histone deacetylase (HDAC) inhibitor. Non-limiting examples of suitable agents, and their concentrations, include those described in subsection II above.

[0071] In another aspect, the present disclosure provides an isolated cell culture of human CD34+ hematopoietic stem cells (HSCs), comprising human CD34+ HSCs cultured in a culture medium comprising a c-kit ligand, a TPOR agonist, a TGFβ pathway agonist, an antioxidant, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, a Notch agonist, and a histone deacetylase (HDAC) inhibitor. In another aspect, the present disclosure provides an isolated cell culture of human CD34+ long-term hematopoietic stem cells (LT-HSCs), comprising human CD34+ LT-HSCs cultured in a culture medium comprising a TGFβ pathway agonist, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, and a histone deacetylase (HDAC) inhibitor. Non-limiting examples of suitable agents, and their concentrations, include those described in subsection II above.

[0072] The present invention is further illustrated by the following examples, which should not be construed as further limiting. The contents of the figures and all references, patents and published patent applications cited throughout this application are expressly incorporated herein by reference. EXAMPLES

[0073] Example 1 : Development of culture protocols for expansion and maintenance of hematopoietic stem cells In this example, a culture medium formulation for the expansion and maintenance of HSCs was developed. The formulation for the expansion and maintenance of hematopoietic stem cells is, for example, CD34 + The cells were cultured and - CD34 + CD38 - CD45RA - CD90 + In a further embodiment, a method for expanding a population of cells, identified as long-term HSCs (LT-HSCs), has been developed.

[0074] In this example, we utilize high-dimensional experimental design (HD-DoE), as previously described in Bukys et al. (2020) Iscience 23:101346. This method employs computerized design geometries to simultaneously test multiple process inputs and provides mathematical modeling of deep effector / response space. This method allows for the discovery of combinatorial signaling inputs that control complex processes, such as cell differentiation. This allows for the testing of multiple plausible key process parameters, which affect output responses, such as gene expression. Gene expression provides a hallmark of the phenotype, for example of human cells, and this method can be applied to identify and understand which signaling pathways control cell fate. In this example, the HD-DOE method was applied with the goal of finding conditions for the expansion and maintenance of HSCs.

[0075] Specifically, to develop formulations for HSCs, agonists and antagonists of multiple signaling pathways (herein referred to as effectors) were tested for their effects on the expression of two sets of 53 preselected genes after 3 days of treatment. Certain genes in the measured subsets were highly enriched in HSCs, including CRHBP, MLLT3, MEG3, MECOM, HOXA5, and GATA2. The selected effectors include small molecules or proteins, some of which are used during in vitro expansion of HSCs.

[0076] To test effectors, experiments with at least eight factors were designed; the experiments allow the evaluation of the response of cells to more than 48 different combinations of effectors at a range of concentrations. To analyze the model, we focused on the expression of genes expressed or enriched in primitive HSCs, such as CRHBP, GATA2, MLLT3, and MEG3. The impact of each effector on gene expression levels is defined by a parameter called the factor contribution, which is calculated for each effector during modeling. All experiments were performed on CD34 cells isolated from umbilical cord blood. + A population of cells was used.

[0077] To identify a formulation for HSC expansion, cells were treated with various effectors in medium containing stem cell factor (SCF) and thrombopoietin (TPO) for 3 days and the gene expression of the cells was modeled. One model showed promising results, especially in terms of upregulation of GATA2, CRHBP, HOXA5, MECOM, and MEG3. Furthermore, in this model, upregulation of NOTCH1 and downregulation of MPO were observed. MPO is a myeloid marker highly expressed on neutrophils and other blood progenitor cells. Previous studies have shown that activation of NOTCH1 enhances HSC self-renewal in vivo (Stier et al. (2002) Blood 99:2369-78).

[0078] As shown in the results summarized in Figure 1, one model in particular showed promising results when optimized for maximum expression of GATA2. In this model, eight factors were tested: LPA, FICZ, Pyrintegrin, Laminin 521, GO693, Vit. C, G-SCF, and Activin A. Three of these effectors (LPA, FICZ, and Vit. C) positively influenced the expression of genes of interest with factor contributions of 20, 21, and 12, respectively. CD44 is a receptor highly expressed on cells undergoing the endothelial to hematopoietic transition, a process crucial for the generation of HSCs (Oatley et al. (2020) Nat Commun. 11:586). Interestingly, the highest levels of CD44 were observed when optimized for GATA2.

[0079] MEG3 is highly expressed in mouse and human HSCs and strongly downregulated in early progenitor cells (Sommerkamp et al. (2019) Sci Rep 9:2110). To bring MEG3 to its maximum expression level, we next optimized the model toward maximum expression of MEG3. Two effectors that exert a significant positive effect on Meg3 expression were identified, including Activin A and Vit. C, which showed factor contributions of 23 and 16, respectively (Figure 2). Despite its small factor contribution to GATA2, Activin A was one of the crucial factors for many other genes enriched in HSCs, including MEG3, HOXA5, and MECOM; therefore, Activin A was included in the formulation.

[0080] Additional HD-DoE experiments were performed to further refine the formulation for HSC maintenance and expansion. From these data, additional gene regulation models were created and used to prepare the expansion protocol. The goal was to evaluate additional factors that could increase the complexity of the signaling input to achieve effective fate control. As before, we focused on the expression of genes abundant in HSCs, as previously described. An eight-factor experiment was performed, testing tropoelastin, lipid mixture, propionate, biotin, geltrex, N-acetylcysteine, prostaglandin E2, and VPA. As in the previous experiment, CD34 + Cells were treated with 48 combinations of these factors for three days and then subjected to gene expression analysis and modelling.

[0081] As shown in the results summarized in Figure 3, when optimized for CRHBP, one factor, VPA (a histone deacetylase inhibitor), had a significant positive impact with a factor contribution of 32. Propionate, biotin, and Geltrex also had positive impacts, but their factor contributions were less than 10 (8, 5, and 6, respectively), and N-acetylcysteine ​​had a positive factor contribution of less than 1.

[0082] Optimization of CRHBP showed promising results in terms of upregulation of HOPX (a gene required for stemness of HSCs) (Lin et al. (2020) Oncogene 39:5112-5123), NOTCH1, SPINK2 (genes enriched in nascent HSCs), and RUNX1 (a gene required for the generation of HSCs during embryonic development) (North et al. (2004) Stem Cells 22:158-68). As propionate, biotin, and geltrex showed low factor contributions in this context and may downregulate other genes enriched in HSCs, these factors were excluded and VPA was maintained. The same experiment was optimized towards maximum expression of GATA2, and three effectors including VPA, prostaglandin E2, and tropoelastin were confirmed to have a significant positive impact on GATA2 expression, showing factor contributions of 33, 25, and 17 (Figure 4). Because treatment with tropoelastin and prostaglandin E2 down-regulates other genes enriched in HSCs, we decided to exclude these factors but retain VPA.

[0083] To further refine the formulation for HSC maintenance and expansion, an additional HD-DoE experiment was performed. Another eight-factor experiment was performed consisting of LPA, Yhhu 3792, fibronectin, TPCA-1, GW9662, Z-vad-fmk, VEGF, and activin A. As in the previous experiment, CD34 + Cells were treated with 48 combinations of these factors for three days, and then gene expression analysis experiments were performed.

[0084] As shown in the results summarized in Figure 5, when optimized for CRHBP, one factor, Activin A (an agonist of the TGFβ family), had a significant positive impact with a factor contribution of 26, confirming our previous results. LPA, Yhhu 3792, and fibronectin also had a positive impact with factor contributions of 8, 19, and 18, respectively. The conditions required for optimization of CRHBP also induced other HSC-related genes, such as HOXA5, NOTCH1, and MEG3. In this condition, LMO2 and LMO4 were also upregulated. Both genes are enriched in HSCs, but are also expressed by other blood progenitor cells. To reduce the complexity of the formulation, we decided to include only Yhhu 3792, a Notch signaling agonist.

[0085] Considering all the models analyzed, and based on the predicted conditions that maximize the expression of genes enriched in HSCs, such as GATA2, CRHBP, HOXA5, MLLT3, MEG3, and NOTCH1, we developed a complex formulation for the maintenance and expansion of HSCs; this formulation is composed of eight effectors, as shown in Table 1 below.

[0086] Table 1. HSC maintenance and expansion culture medium formulation TIFF2024541616000001.tif75170

[0087] Example 2 Factor importance analysis of HSC maintenance and expansion growth medium In this example, to evaluate the impact of the removal of each validated factor identified as described in Example 1, dynamic profile analysis was used to compare the expression levels of the genes of interest in the absence of each finalized factor while leaving the other factors present. This factor importance analysis revealed the degree of importance of each input effector, since the expression levels of the genes of interest reveal whether the desired outcome can be reached. The results of the importance analysis for factors FICZ, LPA, Vit. C, and Activin A are shown in Figures 6A-B. The results of the importance analysis for VPA are shown in Figures 7A-B. The results of the importance analysis for Yhhu 3792 are shown in Figures 8A-B.

[0088] In the formula for HSC expansion, we removed each of the six finalized factors, but left the other five factors present, and evaluated the expression levels of GATA2, HOXA5, and CRHBP compared to when all five factors were present. SCF and TPO are cytokines that affect cell growth and survival, so these cytokines were included in our formula. When FICZ was removed, the value of GATA2 expression decreased from 642 to 512, but there was no change in the expression of HOXA5 and MEG3. In the absence of LPA, the expression of GATA2 decreased, decreasing from 644 to 525. When Vit. C was removed, the level of MEG3 decreased from 82 to 53. Activin A is a crucial factor for MEG3, as its removal reduces the MEG3 level from 81 to 40. Activin A also has a positive effect on GATA2 and HOXA5, but to a lesser extent.

[0089] VPA is a histone deacetylase inhibitor and has been used to expand HSCs (Papa et al. (2018) Blood Adv. 2:2766-2779). In general, this class of drugs can promote chromatin opening, resulting in gene upregulation or repression. VPA was added to the HSC formulation because removal of VPA reduced CRHBP levels from 285 to 138. MEG3 levels were reduced by half (from 106 to 52) when VPA was removed. Finally, GATA2 levels were also reduced by VPA removal, but to a lesser extent.

[0090] The function of the NOTCH pathway in hematopoiesis is complex and there is some debate (see, for example, Huang et al. (2021) Front. Cell Biol. DOI:10.3389 / fcell.2020.606448). However, previous studies have shown that NOTCH stimulation by Delta-1 is involved in the upregulation of human CD34 + CD38 - It has been shown to enhance the repopulation ability of cells. Yhhu 3792 is a new NOTCH agonist first reported in 2018 (Lu et al. (2018) Stem Cells 36:1273-1285). Experiments herein revealed that Yhhu 3792 is a promoter of the HSC phenotype. Upon removal of Yhhu 3792, the level of CRHBP decreased from 202 to 169. Factor importance analysis shows that removing any of the inputs does not have a fatal effect on performance. This is expected due to the high complexity and large number of signaling inputs.

[0091] Example 3 Flow cytometric validation of culture media for the maintenance and expansion of cord blood HSCs To further validate the formulation for HSC culture described in Example 1, CD34+ cord blood-derived cells were cultured for 7 days in medium containing the components shown in Table 1, and markers of LT-HSC status were evaluated using flow cytometry analysis. Markers examined included lineage (CD3, CD14, CD16, CD19, CD20, CD56), CD34, CD38, CD45RA, and CD90. Additionally, as a control, cells were cultured in medium containing SCF and TPO, which are commonly used by others to promote HSC expansion. Other cytokines commonly used to expand HSC, such as IL3, G-CSF, and IL6, were not used because our studies have shown that culturing CD34+ cells in the presence of these cytokines induces myeloid bias. 100,000 cells were plated per condition.

[0092] After culturing the cells for 7 days, flow cytometry analysis was performed. - CD34 + CD38 - CD45RA - CD90 + The results are shown in Figures 9A-B. Flow cytometry analysis confirmed the efficiency of the HSC formulation to promote HSC expansion and maintenance. In the SCF+TPO (control) supply condition, 18.3% of the cells were CD45RA - and CD90 + (Parent gate (CD34 + CD38 - In contrast, in the complex media formulation described in Example 1, 40.9% of the cells were CD45RA - and CD90 + (Parent gate (CD34 + CD38 - ) (40.9%).

[0093] Example 4 : Development of conditions for controlling the dormant state of LT-HSCs The above conditions described in Example 1, which expanded the number of LT-HSCs, were performed under the conditions of continuous expansion. However, the characteristic set of LT-HSCs is always associated with quiescence; therefore, at a critical level, the resulting expanded CD34+ cells are not identical to the bone marrow-resident LT-HSC population. For that reason, additional HD-DOE experiments were performed in basal medium without SCF and TPO. In these experiments, the design consisted of 12 factors, including SCF, TPO, FLT-3L, IGFII, Yoda-1, and cytosporin B, in addition to the factors in Table 1.

[0094] One model, the results of which are summarized in Figure 10, showed promising results, especially with regard to the upregulation of CRHBP, HOPX, CD34, and LMO2. The levels of CRHBP were extremely high in this experiment, reaching levels of 1118. Interestingly, many of the factors listed in Table 1 were required to induce maximal expression of CRHBP in the absence of cytokines, confirming the importance of these factors for stemness.

[0095] The optimal conditions for inducing maximum CRHBP levels are shown in Table 2 below.

[0096] (Table 2) TIFF2024541616000002.tif49166

[0097] To compare the media in Table 2 with conventional HSC culture and expansion methods (SCF+TPO), through mathematical modeling, we generated predicted levels of genes associated with stem cell phenotype, as well as predicted levels of lineage-specific genes, when cultured in either conventional media (SCF+TPO) or the media in Table 2. These predicted gene levels are summarized below in Table 3.

[0098] (Table 3) TIFF2024541616000003.tif125170

[0099] As expected, proliferation (MKI67 levels) was low when cells were cultured in the formulation in Table 2, which does not contain SCF and TPO. However, stem cell-associated genes such as CRHBP, MEG3, HOPX, and CD34 were highly expressed in the medium in Table 2 compared to the SCF+TPO condition. Meanwhile, KLF1 and MPO, two markers of lineage-committed cells, were highly expressed in the SCF+TPO condition.

[0100] Equivalent Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein which equivalents are intended to be encompassed by the claims appended hereto.

Claims

1. A method for expanding or maintaining human CD34+ hematopoietic stem cells (HSCs), comprising culturing the human CD34+ HSCs in a culture medium comprising a c-kit ligand, a TPOR agonist, a TGFβ pathway agonist, an antioxidant, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, a Notch agonist, and a histone deacetylase (HDAC) inhibitor.

2. The method of claim 1, wherein the c-kit ligand is stem cell factor (SCF).

3. The method of claim 1, wherein the TPOR agonist is thrombopoietin (TPO).

4. The method of claim 1, wherein the TPOR agonist is eltrombopag, TA-316, TPO agonist 1, avatrombopag, or lusutrombopag.

5. The method of claim 1, wherein the TGFβ pathway agonist is activin A.

6. The method of claim 1, wherein the TGFβ pathway agonist is alantolactone.

7. 2. The method of claim 1, wherein the antioxidant is vitamin C.

8. 2. The method of claim 1, wherein the antioxidant is ascorbic acid, glutathione, ebselen, N-acetyl-L-cysteine, or alpha-tocopherol.

9. 2. The method of claim 1, wherein the bioactive phospholipid is lysophosphatidic acid (LPA).

10. 2. The method of claim 1, wherein the bioactive phospholipid is sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P), or lysophosphatidylcholine (LPC).

11. 2. The method of claim 1, wherein the AhR agonist is 6-formylindolo[3,2-b]carbazole (FICZ).

12. 2. The method of claim 1, wherein the AhR agonist is norisoboldine, pifithrin-alpha hydrobromide, MeBIO, ITE, or 10-Cl-BBQ.

13. The method of claim 1, wherein the Notch agonist is Yhhu 3792.

14. The method of claim 1, wherein the Notch agonist is Jagged 1-2 or DLL1-4.

15. 2. The method of claim 1, wherein the HDAC inhibitor is valproic acid (VPA).

16. The HDAC inhibitor is selected from the group consisting of vorinostat, entinostat, panobinostat, trichostatin A, mocetinostat, 4-phenylbutyric acid, ACY-775, GSK3117391, belinostat, romidepsin, MC1568, tubastatin A, gibinostat, dacinostat, CUDC-101, xinostat, pracinostat, PCI-34051, droxinostat, abexinostat, RGFP966, AR-42, ricorinostat, tacedinaline, fimepinostat, sodium butyrate, curcumin, M344, tubacin, RG2833, resminostat, divalproex sodium, scriptaid, sodium phenylbutyrate, tubastatin A, sinapic acid , TMP269, CAY10683, TMP195, UF010, tasquinimod, SKLb-23bb, isoguanosine, NKL22, sulforaphane, BRD73594, citalinostat, suberohydroxamic, BRD3308, splitomycin, HPOB, LMK235, biphenyl-4-sulfonyl chloride, nextulastat A, BML-210, TC-H106, SR-4370, TH34, tushidinostat, SIS17, parthenolide, wt161, CAY10603, ACY738, raddeanin A, tinostamustin, domatinostat, BG45, and ITSA-1.

17. The method of claim 1, wherein the CD34+ HSCs are derived from umbilical cord blood.

18. The method of claim 1, wherein the CD34+ HSCs are derived from bone marrow.

19. The method of claim 1, wherein the CD34+ HSCs are cultured for at least 6 days.

20. The method of claim 1, wherein the CD34+ HSCs have a phenotype of Lin-CD34+CD38-CD45RA-CD90+.

21. 1. A method for expanding or maintaining human CD34+ hematopoietic stem cells (HSCs), comprising culturing human CD34+ HSCs in a culture medium comprising stem cell factor (SCF), thrombopoietin (TPO), activin A, vitamin C, lysophosphatidic acid (LPA), 6-formylindolo[3,2-b]carbazole (FICZ), Yhhu 3792, and valproic acid (VPA).

22. 22. The method of claim 21, wherein SCF is present at a concentration of 10 ng / ml, TPO is present at a concentration of 100 ng / ml, activin A is present at a concentration of 20 ng / ml, vitamin C is present at a concentration of 100 μM, LPA is present at a concentration of 200 nM, FICZ is present at a concentration of 500 nM, Yhhu 3792 is present at a concentration of 750 nM, and VPA is present at a concentration of 150 μM.

23. A culture medium for expanding or maintaining human CD34+ hematopoietic stem cells (HSCs), comprising a c-kit ligand, a TPOR agonist, a TGFβ pathway agonist, antioxidants, bioactive phospholipids, an aryl hydrocarbon receptor (AhR) agonist, a Notch agonist, and a histone deacetylase (HDAC) inhibitor.

24. 24. The culture medium of claim 23, wherein the c-kit ligand is stem cell factor (SCF).

25. 24. The culture medium of claim 23, wherein the TPOR agonist is thrombopoietin (TPO).

26. 24. The culture medium of claim 23, wherein the TPOR agonist is eltrombopag, TA-316, TPO agonist 1, avatrombopag, or lusutrombopag.

27. 24. The culture medium of claim 23, wherein the TGFβ pathway agonist is activin A.

28. 24. The culture medium of claim 23, wherein the TGFβ pathway agonist is alantolactone.

29. 24. The culture medium of claim 23, wherein the antioxidant is vitamin C.

30. 24. The culture medium of claim 23, wherein the antioxidant is ascorbic acid, glutathione, ebselen, N-acetyl-L-cysteine, or alpha-tocopherol.

31. 24. The culture medium of claim 23, wherein the bioactive phospholipid is lysophosphatidic acid (LPA).

32. 24. The culture medium of claim 23, wherein the bioactive phospholipid is sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P), or lysophosphatidylcholine (LPC).

33. 24. The culture medium of claim 23, wherein the AhR agonist is 6-formylindolo[3,2-b]carbazole (FICZ).

34. 24. The culture medium of claim 23, wherein the AhR agonist is norisoboldine, pifithrin-alpha hydrobromide, MeBIO, ITE, or 10-Cl-BBQ.

35. 24. The culture medium of claim 23, wherein the Notch agonist is Yhhu 3792.

36. The culture medium of claim 23, wherein the Notch agonist is Jagged 1-2 or DLL1-4.

37. 24. The culture medium of claim 23, wherein the HDAC inhibitor is valproic acid (VPA).

38. The HDAC inhibitor is selected from the group consisting of vorinostat, entinostat, panobinostat, trichostatin A, mocetinostat, 4-phenylbutyric acid, ACY-775, GSK3117391, belinostat, romidepsin, MC1568, tubastatin A, gibinostat, dacinostat, CUDC-101, xinostat, pracinostat, PCI-34051, droxinostat, abexinostat, RGFP966, AR-42, ricorinostat, tacedinaline, fimepinostat, sodium butyrate, curcumin, M344, tubacin, RG2833, resminostat, divalproex sodium, scriptaid, sodium phenylbutyrate, tubastatin, 24. The culture medium of claim 23, wherein the active ingredient is selected from the group consisting of sirolimus A, sinapic acid, TMP269, CAY10683, TMP195, UF010, tasquinimod, SKLb-23bb, isoguanosine, NKL22, sulforaphane, BRD73594, citalinostat, suberohydroxamic, BRD3308, splitomycin, HPOB, LMK235, biphenyl-4-sulfonyl chloride, nextulastat A, BML-210, TC-H106, SR-4370, TH34, tushidinostat, SIS17, parthenolide, wt161, CAY10603, ACY738, raddeanin A, tinostamustin, domatinostat, BG45, and ITSA-1.

39. 24. The culture medium of claim 23, comprising stem cell factor (SCF), thrombopoietin (TPO), activin A, vitamin C, lysophosphatidic acid (LPA), 6-formylindolo[3,2-b]carbazole (FICZ), Yhhu 3792, and valproic acid (VPA).

40. 40. The culture medium of claim 39, wherein SCF is present at a concentration of 10 ng / ml, TPO is present at a concentration of 100 ng / ml, activin A is present at a concentration of 20 ng / ml, vitamin C is present at a concentration of 100 μM, LPA is present at a concentration of 200 nM, FICZ is present at a concentration of 500 nM, Yhhu 3792 is present at a concentration of 750 nM, and VPA is present at a concentration of 150 μM.

41. An isolated cell culture of human CD34+ hematopoietic stem cells (HSCs), comprising human CD34+ HSCs cultured in a culture medium comprising a c-kit ligand, a TPOR agonist, a TGFβ pathway agonist, an antioxidant, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, a Notch agonist, and a histone deacetylase (HDAC) inhibitor.

42. 1. A method for maintaining human CD34+ long-term hematopoietic stem cells (LT-HSCs), comprising: Culturing human CD34+ HSCs in a culture medium comprising a TGFβ pathway agonist, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, and a histone deacetylase (HDAC) inhibitor. Including, the culture medium lacks stem cell factor (SCF) and thrombopoietin (TPO); The method.

43. 43. The method of claim 42, wherein the TGFβ pathway agonist is activin A, the bioactive phospholipid is lysophosphatidic acid (LPA), the AhR agonist is 6-formylindolo[3,2-b]carbazole (FICZ), and the HDAC inhibitor is valproic acid (VPA).

44. The LT-HSCs express CD34, which also expresses CRHBP, HOPX, and LMO2. + The method of claim 42, which is a cell.

45. A culture medium for maintaining human CD34+ long-term hematopoietic stem cells (LT-HSCs), comprising a TGFβ pathway agonist, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, and a histone deacetylase (HDAC) inhibitor, wherein the culture medium lacks stem cell factor (SCF) and thrombopoietin (TPO).

46. 1. An isolated cell culture of human CD34+ long-term hematopoietic stem cells (LT-HSCs), comprising human CD34+ LT-HSCs cultured in a culture medium comprising a TGFβ pathway agonist, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, and a histone deacetylase (HDAC) inhibitor, the culture medium lacks stem cell factor (SCF) and thrombopoietin (TPO); The culture.